2 REITs Yielding up to 7.6% and a Diabetes Leader

Greetings Friends,

I hope everyone had a great Thanksgiving. That means we’ve only got 30 days of 2013 left. Christmas is right around the corner. This year has flown by.November is usually a good month for stocks, and that’s what we just saw. The S&P 500 gained 2.75% on the month, now up 24% on the year.December is usually a good month for stocks as well.

The Santa Claus rally has been in play for the last few years. If we see it this year the S&P 500 will have plenty of upward momentum going into the end of the year.That shows up on the chart. In spite of worries about a big pullback or even crash, the market keeps charging higher. Take a look at the bullish trend below.

We’ve seen that strong market support some of our favorite stocks.

  • Celgene, Inc. (CELG) +105%
  • Biogen Idec (BIIB) +100%
  • Sturm Ruger (RGR) +74%
  • Intercontinental Exchange (ICE) +73%
  • Amerisource Burgen (ABC) +65%
  • Federal Express (FDX) +53%
  • Google, Inc. (GOOG) +50%
  • Harley Davidson (HOG) +39
  • Stryker Corp (SYK) +37%
  • Visa, Inc. (V) +35%

Looking forward, I’m looking for a strong finish to the year and upward momentum going into 2014.

There are definitely land mines. But the Fed and other central banks around the world remain committed to supporting the economy and market. And as long as that sticks, stocks are going to keep moving higher.

Shifting into the articles:

There’s a leading diabetes stock I like, a company that sells expensive art and a few REITs with big yields up to 7.6%. I only write about stocks and ideas I really believe in, so these articles are a great place to find my best investment ideas with tickers.

Own a Piece of the Empire State Building with This IPO

“Manhattan is the most exclusive real estate market in the world. The tiny, 34-square-mile island is home to Wall Street, the global headquarters of the United Nations and some of the most powerful and influential companies in the world.That exclusivity has driven big gains for one of Manhattan’s most prized properties. Since going public in the spring of 2010, Madison Square Garden (NYSE: MSG) is up a market-crushing 198%.But if you missed out on that impressive run, don’t worry. The most exclusive real estate market in the world is setting the stage for another big winner. Clocking in at $1.3 billion, this company’s recent IPO was the second-largest ever for a U.S. REIT (real-estate investment trust). It controls more than 8 million square feet of some of the most desirable commercial real estate in the world. And it also pays investors to own shares with a solid dividend yield that is higher than the benchmark 10-year Treasury.” –Michael Vodicka @ Street Authority 

“$142 million for a Francis Bacon triptych. $120 million for a pastel by Edvard Munch. $106 million for an oil painting by Picasso. After a slow 2012, the fine-art market is back. Stock market gains worldwide and growing wealth in Asia have lifted prices to new all-time highs. That includes the recent $142 million for the Francis Bacon triptych, eclipsing last year’s record $120 million for Munch’s “The Scream.”The fine-art market is trading just like the stock market. Buyers are stepping out and lifting the bid. That’s putting a lot of cash into the pockets of investors with rare collections. But art connoisseurs aren’t the only ones cashing in. I want to tell you about a global leader in the auctioneer business that is also cashing in on these nine-figure masterpieces.”

–Michael Vodicka @Street Authority  

A Company Solving the Global Diabetes Crisis is a ‘Buy’

 “Diabetes is no longer solely an American epidemic. The Journal of the American Medical Association just released a study that shows 11.6% of Chinese adults have the debilitating disease, surpassing America’s 11.3%. With a population topping 1 billion, China is now home to more than 100 million people suffering from diabetes — a third of the global diabetes population.

And with emerging markets gaining more access to middle-class amenities such as high-fat food, the trend is accelerating. The International Diabetes Federation projects that more than 550 million people will be diagnosed with diabetes by 2030, up from 371 million diabetes patients in 2012. That’s a huge opportunity for the global leader in diabetes medication and treatments. Not only is this market leader home to five of the top 10 selling diabetes medications in the world, it’s also developing a deep pipeline of next-generation diabetes drugs and is protected by a huge competitive moat. That has driven an outsize gain of 58% in the past two years:”

–Michael Vodicka @ Street Authority

“One of the boldest energy predictions of the past 10 years is about to become reality. According to the International Energy Agency, the U.S. will eclipse Russia and Saudi Arabia and become the world’s top oil producer by 2015. And looking forward, that trend is going to accelerate, with the agency saying that booming production has the U.S. on track for energy independence in 20 years.

But while that bullish trend will give energy companies a big boost, it’s also going to have a huge effect on local and regional economies. High-production states such as North Dakota, South Dakota and Nebraska already enjoy the lowest levels of unemployment in the country. And as energy companies continue to add tens of thousands of new employees, those strong local and regional economies will fuel record demand for temporary housing, permanent housing and commercial real estate. That’s why I’m bullish on a little-known group of real estate investment trusts (REITs) that are exclusively focused on strong regional economies in position to profit from the North American shale boom.”

–Michael Vodicka @ Street Authority    

This report is for entertainment purposes only. Every investor should consult with an investment advisor before making investment decisions. The Vodicka Group, Inc. is not a broker/dealer. We do not receive compensation for mentioning stocks. At various times, the clients, publishers and employees of Vodicka Group, Inc., may buy or sell the securities discussed for purposes of investment or trading.

ABOUT THE AUTHOR

Michael Vodicka

Michael Vodicka is the president and founder of the Vodicka Group Inc., a licensed investment advisor (Series 65) and a financial journalist.